PI3K/Akt/mTOR · target hub

STRADA

STE20-related kinase adapter protein alpha (STRADA)

STRADA is a Autophagy/AMPK/DDR crosstalk with mTOR on the PI3K/Akt/mTOR axis. Pseudokinase which, in complex with CAB39/MO25 (CAB39/MO25alpha or CAB39L/MO25beta), binds to and activates STK11/LKB1. Adopts a closed conformation typical of active protein kinases and binds STK11/LKB1 as a pseudosubstrate, promoting conformational change of STK11/LKB1 in an ac… It is indexed under "AMPK & LKB1 (energy stress antagonism of mTORC1)" on our pathway page for antibodies, inhibitors, and assay guidance.

Back to pathway overviewSearch: STRADAUniProt (A0A1W2PPG2)

Research notes

  • Combine with other genes in the same hub block via genetics or pharmacology to test non-redundant roles of STRADA.
  • Annotate PIK3CA/PTEN and upstream RTK–Ras context when reading p-AKT, mTORC1/2, or lipid outputs.
  • Verify antibody clone, phospho-site, and stimulation; include KD/KO or inhibitor controls.

On the pathway hub (sections)

Genetic lesions & expression context (quick reference)

Type / exampleDomain / context (brief)
Expression contextTissue/cell-type–dependent expression
Rare variantsSporadic variants—require functional validation
Pathway couplingCo-occurs with neighboring nodes on the hub

Naming and prevalence vary by cohort and assay—annotate clinically with COSMIC, ClinVar, OncoKB, and datasheets; research context only.

Assay readouts for STRADA

  • Autophagy: LC3-II, p62, ULK1 complex phospho-status under mTORC1 restraint.
  • AMPK: p-ACC, p-TSC2 in energy-stress contexts.
  • DDR: γH2AX, CHK1/2 phosphorylation in damage models.
  • Pair with Akt/mTOR inhibitors to map parallel survival programs.

STRADA experimental notes

Examples below reflect common literature and public resources (e.g., CCLE, DepMap)—validate genotypes, expression, and passage in your own stocks before committing assays.

[1] Cell lines commonly used for STRADA studies (examples)

  • Tool lines: U2OS, MEFs, HEK293T, HCT116, A549—screen by STRADA expression and pathway context (CCLE/DepMap).
  • Combine with neighbors (STK11, STRADB, CAB39, CAB39L) via KD/pharmacology to test non-redundancy.
  • Overexpression/rescue in HEK293T supports mechanism and IP workflows.
  • Isogenic/CRISPR models separate pathway dependency from bypass survival.

[2] Cell samples for STRADA Western blot

  • Whole-cell lysates—optimize RIPA/NP-40 per antibody; phosphatase inhibitors for phospho blots.
  • Stimulation: serum starvation ± insulin/EGF or amino-acid withdrawal/refeed as relevant.
  • Controls: siRNA/shRNA, CRISPR KO, or inhibitors to validate band specificity.
  • Loading: BCA normalization; subcellular fractionation when needed.

[3] Tissue samples for STRADA Western blot

  • Matched tumor/adjacent frozen tissues after pathology review.
  • Mouse GEMM or xenografts—mind species antibody cross-reactivity.
  • Primary cells/PDCs when ethically approved.
  • FFPE needs specialized extraction; frozen tissue preferred for phospho work.

[4] Cell samples for STRADA immunoprecipitation

  • Tagged overexpression: HEK293T FLAG/HA-STRADA for complex capture.
  • Endogenous IP: high-expression lines; often ≥1–5×10⁶ cells per IP.
  • Stimulation: ligand or nutrient treatments enrich interactions—pilot time courses.
  • Controls: isotype IgG, empty vector, KD/KO negatives.

Human tissues and primary cells require ethics/IRB approval; tumors are heterogeneous—record histotype, site, and preservation conditions.

Bypass & related pathways

Models & genetics note

Overexpression vs endogenous STRADA can differ in dosage, splicing, and compartmentation—in organoids/PDX, record passage, matrix, and drug history.

Quick search presets

STRADASTRADA antibodyPI3K inhibitormTOR inhibitor

STRADA-related antibodies (keyword-biased)

Adds STRADA keyword bias atop the PI3K/Akt/mTOR antibody pool—if sparse, use presets above or global search.

Neighboring targets (same hub)

STK11STRADBCAB39CAB39LPRKAA1PRKAA2PRKAB1PRKAB2

External databases & resources

FAQ

This content supports research reagents and pathway education—not medical advice. Annotate mutations, drug indications, and protocols with authoritative databases, datasheets, and institutional oversight.

Last reviewed: 2026-05-18

Related on this site

See the PI3K/Akt/mTOR hub for neighboring nodes and assay guidance—cross-check MAPK, RTK, metabolism, and autophagy pages as needed.

PI3K/Akt/mTOR·MAPK/ERK·Receptor tyrosine kinase·Metabolism